Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Completed · Phase 2 · Has a placebo group

Conditions studied: Hyperlipidemia

In brief

To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

Key facts

Study ID
NCT00559962
Run by
Aegerion Pharmaceuticals, Inc.
People needed
260
Starts
2007-10-01
Expected to finish
2008-11-01
Last updated by the study team
2018-02-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.